Precigen, Inc. (PGEN) fair value analysis
Nasdaq · Updated 2026-09-07
Precigen, Inc. is a biotechnology company that develops gene editing and cell therapy technologies for therapeutic applications. The company operates primarily in the United States within the healthcare and life sciences sector.
Valuation status
Awaiting full valuationPGEN does not yet have sufficient validated earnings history for a full Forward Fair Value verdict under our standards — we require at least six validated trailing price-to-earnings windows before publishing one. TickrTrends re-evaluates every covered stock weekly; a verdict publishes automatically once enough validated history accumulates.
- Last price
- $6.61
- Sector
- Healthcare
- 12-month range
- $3.34–$6.61
Derived indicators
Coarse bands from TickrTrends' weekly models; exact figures are part of the full report.
- Quality grade
- D
- Leverage
- High
- RSI zone
- Neutral
- 50/200-day trend
- Uptrend
- 52-week position
- The top quarter of its range
What our data shows for PGEN
- Shares are trading in the upper third of their 12-month price range of $3.34–$6.61.
- The 14-day relative strength index sits at a neutral 52.
The exact numbers are one step away
- The precise Forward Fair Value dollar figure for PGEN
- Exact discount / premium to today's price
- The normalized historical P/E behind the estimate, and how many quarters support it
- Forward EPS input and fiscal-year basis
- Screeners and rankings across the full S&P 500 and Nasdaq universes
How Forward Fair Value works
TickrTrends computes a Forward Fair Value for every covered stock each week: a conservatively normalized historical price-to-earnings multiple is applied to the analyst-consensus earnings estimate for the next full fiscal year. Every input window is validated for continuity and every result is screened for plausibility before publication.
Recent PGEN news
TickrTrends' derived news-sentiment signal for PGEN is currently leaning positive, computed from recent coverage.
- Precigen (PGEN) Director Jeffrey Kindler Sells 185,000 Shares (gurufocus.com, 2026-08-29)
TickrTrends take: Director Jeffrey Kindler's sale of 185,000 shares represents a significant insider transaction at Precigen, a Healthcare sector company currently awaiting full valuation assessment from TickrTrends. Large insider share dispositions can provide important signals about management's confidence in near-term prospects, making such transactions particularly relevant for investors evaluating the company's true valuation range. As TickrTrends works toward establishing comprehensive valuation metrics for PGEN, tracking patterns of insider buying and selling activity may help contextualize what company leadership believes about future value creation. - Are You Looking for a Top Momentum Pick? Why Precigen, Inc. (PGEN) is a Great Choice (zacks.com, 2026-08-14)
TickrTrends take: Precigen operates in the Healthcare sector where momentum-driven movements can sometimes diverge from fundamental valuation metrics. TickrTrends currently has an awaiting full valuation status for PGEN, meaning a comprehensive valuation assessment has not yet been completed. Investors focused on valuation fundamentals may want to monitor when a complete valuation analysis becomes available to better understand how PGEN's current price aligns with its underlying business metrics. - Precigen Stock Has To Grow Into Its Valuation (NASDAQ:PGEN) (seekingalpha.com, 2026-08-08)
TickrTrends take: Precigen operates in the Healthcare sector where valuation expectations can shift significantly based on pipeline progress and commercial execution. The company's current TickrTrends status reflects an awaiting full valuation stance, suggesting that key metrics remain under evaluation before a definitive assessment can be reached. Investors monitoring valuation should track whether Precigen demonstrates the operational and financial growth necessary to justify its current market positioning.
What people are saying
Follow the PGEN conversation: Stocktwits · Reddit · X
TickrTrends weekly updates
- 2026-09-07 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-06 — No material change this week: the verdict, bands and grades all held steady.
- 2026-08-31 — TickrTrends initiated weekly Forward Fair Value coverage of this stock.
Frequently asked questions
Is PGEN stock undervalued?
PGEN does not yet have sufficient validated earnings history for a full Forward Fair Value verdict under TickrTrends' standards; it is re-evaluated every week.
What is PGEN's TickrTrends verdict?
PGEN is currently marked 'Awaiting full valuation' - a verdict publishes automatically once at least six validated trailing P/E windows accumulate.
Is PGEN overbought or oversold?
PGEN's 14-day RSI is in neutral territory - neither overbought nor oversold.